Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours Β· Estimated delivery Aug 29 - Sep 3
The agency does not walk into every med spa to monitor what they inject, nor does it monitor whether spas advertise non-FDA-approved treatments
weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists
Cardiovascular outcome trials for tirzepatide are ongoing, but the favorable effects on intermediate markers suggest probable long-term cardiovascular benefit
No studies show that microdosing gives the same outcomes
2
US$ 25.52
US$ 23.46
US$ 26.83
US$ 29.90
US$ 24.52
US$ 25.31
US$ 21.97
US$ 26.50
US$ 20.90
